SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Greencare Capital exits cannabis to focus on crypto and other sectors

    By
    Home / Greencare Capital exits cannabis to focus on crypto and other sectors

    Greencare Capital, which to date has focused solely on investments in medical cannabis, CBD and related areas, has announced it will be exiting the industry and changing its investment strategy due the lack of performance in the sector.

    Greencare Capital’s board of directors has stated that the CBD sector had not been performing well. This, alongside developments in the UK related to Novel Foods, would likely cause short to medium-term turbulence in the market.  

    Additionally, the board advised that, within Europe, novel foods legislation is still to be agreed and that reaching such agreement has been much slower than initially anticipated, and as a result, cannabis and CBD investments within Europe have proven difficult.

    Read more: C-END – a blockchain solution for the cannabis industry

    With continued lack of performance, the company has now concluded that it is in the best interests of all shareholders to withdraw from the medical cannabis, CBD and related wellness markets.

    The company will be adopting a new investment strategy based on private equity style investing in technology-driven businesses, and will now be named MaxRS Ventures plc to reflect its change in investment strategy.

    Four sectors of initial focus have been identified, including life sciences, crypto businesses and assets that use crypto technology, impact investing, such as environmental and renewables, and retail.

    If shareholders approve, Greencare will be implementing a growth incubator/pre-IPO investment philosophy as its investment strategy, whereby it will seek out early-stage or undervalued later-stage businesses with strong upside potential, with the objective of acquiring, funding, growing and selling on the investments through the public markets at enhanced valuations.

    The board will not restrict the jurisdiction of investments since the application of technology is not constrained by geographic borders, however, it would expect that it will consider more investments in Europe.

    The board of Greencare has a wide experience in venture, pre-IPO and Private Equity investing, having grown a number of businesses through to sale and to listing on public markets in sectors that include technology, retail, real estate, and life sciences.  The intention is to add an advisory board to the company to enhance knowledge in other areas as appropriate based on the opportunities being considered.

    10 June 2026 · Berlin Sales end May 29

    European Cannabis
    Insights Summit

    From €216

    200+ industry leaders. Exclusive German market data. A half-day briefing for B2B operators in Europe's most important emerging cannabis market.

    Stephanie Price

    Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine ‘Game Theory’ focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on “Medical Cannabis Explained”.

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free